Patents by Inventor Kathleen L. Berkner
Kathleen L. Berkner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8603777Abstract: Methods are disclosed for producing proteins having biological activity for blood coagulation mediated by Factor VIIa or Factor IX. The proteins are produced by mammalian host cells which have been stably transfected with a DNA construct containing a nucleotide sequence which codes at least partially for either Factor VII or Factor IX. The nucleotide sequence comprises a first nucleotide sequence encoding a calcium binding domain, joined to a second nucleotide sequence positioned downstream of the first sequence. The second sequence encodes a catalytic domain for the serine protease activity of either Factor VIIa or Factor IX. The joined sequences code for proteins having substantially the same biological activity for blood coagulation as either Factor VIIa or Factor IX.Type: GrantFiled: September 25, 1991Date of Patent: December 10, 2013Assignee: ZymoGenetrics, Inc.Inventors: Frederick S. Hagen, Mark J. Murray, Sharon J. Busby, Kathleen L. Berkner, Margaret Y. Insley, Richard G. Woodbury, Charles L. Gray
-
Publication number: 20040197370Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The modified Factor VII may be used in conjunction with stents to inhibit coagulation, vascular restenosis, and/or platelet deposition.Type: ApplicationFiled: December 17, 2003Publication date: October 7, 2004Applicant: Novo Nordisk Health Care AGInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Publication number: 20040087498Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: ApplicationFiled: October 1, 2002Publication date: May 6, 2004Applicant: Novo Nordisk Health Care AGInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 6168789Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.Type: GrantFiled: November 10, 1998Date of Patent: January 2, 2001Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 6039944Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: GrantFiled: June 5, 1995Date of Patent: March 21, 2000Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 5861374Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modification renders Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: GrantFiled: February 12, 1996Date of Patent: January 19, 1999Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.Inventors: Kathleen L Berkner, Lars Christian Petersen, Charles E. Hart
-
Patent number: 5833982Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.Type: GrantFiled: June 7, 1996Date of Patent: November 10, 1998Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 5824639Abstract: Factor VII of the coagulation cascade is modified to act as an anticoagulant. Amino acid modifications are employed to produce a modified Factor VII having a substantially reduced susceptibility to activation by enzymes which typically activate wild-type Factor VII. The modified Factor VII is able to compete with wild-type Factor VII and/or VIIa for binding tissue factor, inhibiting clotting activity. As the modified Factor VII acts specifically to interrupt the coagulation cascade, pharmaceutical compositions of modified Factor VII may be administered in place of, or in conjunction with lower doses of, conventional anticoagulant therapies.Type: GrantFiled: November 12, 1993Date of Patent: October 20, 1998Assignee: ZymoGenetics, Inc.Inventor: Kathleen L. Berkner
-
Patent number: 5817788Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: GrantFiled: October 24, 1994Date of Patent: October 6, 1998Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 5788965Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: GrantFiled: June 7, 1995Date of Patent: August 4, 1998Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 5516650Abstract: Methods are disclosed for producing a protein which has substantially the same biological activity as human protein C or human activated protein C. The protein is produced by mammalian host cells transfected with a plasmid capable of integration in mammalian host cell DNA. The plasmid includes a promoter followed downstream by a nucleotide sequence which encodes a protein having substantially the same structure and/or activity as human protein C or human activated protein C the nucleotide sequence being followed downstream by a polyadenylation signal.Type: GrantFiled: April 8, 1994Date of Patent: May 14, 1996Assignee: Zymogenetics, Inc.Inventors: Donald C. Foster, Mark J. Murray, Kathleen L. Berkner
-
Patent number: 5288629Abstract: Factor VII of the coagulation cascade is modified to act as an anticoagulant. Amino acid modifications are employed to produce a modified Factor VII having a substantially reduced susceptibility to activation by enzymes which typically activate wild-type Factor VII. The modified Factor VII is able to compete with wild-type Factor VII and/or VIIa for binding tissue factor, inhibiting clotting activity. As the modified Factor VII acts specifically to interrupt the coagulation cascade, pharmaceutical compositions of modified Factor VII may be administered in place of, or in conjunction with lower doses of, conventional anticoagulant therapies.Type: GrantFiled: September 21, 1992Date of Patent: February 22, 1994Assignee: ZymoGenetics, Inc.Inventor: Kathleen L. Berkner
-
Patent number: 4959318Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C and recombinant transfer vectors comprising these sequences are disclosed.Methods are disclosed for producing a protein which has substantially the same biological activity as human protein C. The protein, which may be in the form of activated protein C, is produced by mammalian host cells transfected with a plasmid capable of integration in mammalian host cell DNA. The plasmid includes a promoter followed downstream by a nucleotide sequence which encodes a protein having substantially the same structure and/or activity as human protein C, the nucleotide sequence being followed downstream by a polyadenylation signal.Type: GrantFiled: October 29, 1986Date of Patent: September 25, 1990Assignee: ZymoGenetics, Inc.Inventors: Donald C. Foster, Mark J. Murray, Kathleen L. Berkner
-
Patent number: 4784950Abstract: Methods are disclosed for producing proteins having biological activity for blood coagulation mediated by Factor VIIa. The proteins are produced by mammalian host cells which have been stably transfected with a DNA construct containing a nucleotide sequence which codes at least partially for either Factor VII. The nucleotide sequence comprises a first nucleotide sequence encoding a calcium binding domain, joined to a second nucleotide sequence positioned downstream of the first sequence. In particular, the first nucleotide sequence may be derived from a genomic clone or cDNA clone of Factor VII. The second sequence encodes a catalytic domain for the serine protease activity of Factor VIIA. The joined sequences code for proteins having substantially the same biological activity for blood coagulation as Factor VIIa.Type: GrantFiled: December 16, 1986Date of Patent: November 15, 1988Assignee: ZymoGenetics, Inc.Inventors: Frederick S. Hagen, Mark J. Murray, Sharon J. Busby, Kathleen L. Berkner, Margaret Y. Insley, Richard G. Woodbury, Charles L. Gray